Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2018
At a glance
- Drugs CV 301 (Primary) ; MSB 0011359C (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.
- 16 Mar 2018 Planned initiation date changed from 02 Mar 2018 to 22 Mar 2018.
- 27 Feb 2018 Planned initiation date changed from 28 Feb 2018 to 2 Mar 2018.